Sacituzumab Govitecan (IMMU-132) in treatment-resistant uterine serous carcinoma: A case report.

about

Sacituzumab Govitecan (IMMU-132) in treatment-resistant uterine serous carcinoma: A case report.

Item

http://www.wikidata.org/entity/Q55456064

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Sacituzumab Govitecan (IMMU-13 ...... rous carcinoma: A case report.

@en

Sacituzumab Govitecan

@nl

type

Item

label

Sacituzumab Govitecan (IMMU-13 ...... rous carcinoma: A case report.

@en

Sacituzumab Govitecan

@nl

prefLabel

Sacituzumab Govitecan (IMMU-13 ...... rous carcinoma: A case report.

@en

Sacituzumab Govitecan

@nl

P1476

Sacituzumab Govitecan (IMMU-13 ...... rous carcinoma: A case report.

@en

P2093

Alessandro D Santin

http://www.w3.org/2001/XMLSchema#string

Chanhee Han

http://www.w3.org/2001/XMLSchema#string

David M Goldenberg

http://www.w3.org/2001/XMLSchema#string

Peter E Schwartz

http://www.w3.org/2001/XMLSchema#string

Robert M Sharkey

http://www.w3.org/2001/XMLSchema#string

Serengulam V Govindan

http://www.w3.org/2001/XMLSchema#string

Stefania Bellone

http://www.w3.org/2001/XMLSchema#string

P2860

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer

Trop-2 protein overexpression is an independent marker for predicting disease recurrence in endometrioid endometrial carcinoma.

Uterine serous papillary carcinomas overexpress human trophoblast-cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized anti-Trop-2 monoclonal antibody.

Trop-2 overexpression in poorly differentiated endometrial endometrioid carcinoma: implications for immunotherapy with hRS7, a humanized anti-trop-2 monoclonal antibody.

First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors

Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC).

Management of women with uterine papillary serous cancer: a Society of Gynecologic Oncology (SGO) review.

Therapy of Advanced Non-Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan.

Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer.

Sacituzumab Govitecan, a Novel Antibody--Drug Conjugate, in Patients With Metastatic Platinum-Resistant Urothelial Carcinoma.

P304

37-40

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

case report

P356

10.1016/J.GORE.2018.05.009

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-05-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29977989

http://www.w3.org/2001/XMLSchema#string

P932

6030029

http://www.w3.org/2001/XMLSchema#string